CING (Cingulate) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


CING Cingulate Inc CING
35 GF Score
Price $5.46
! 1 Warning Sign
View Full Analysis

What is Cingulate Payments of Debt?

Cingulate CING +2.63% 35 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CING with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Cingulate's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Cingulate's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Cingulate Payments of Debt Related Terms

Cingulate Payments of Debt Historical Data

* Premium members only.

The historical data trend for Cingulate's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Payments of Debt Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -0.94 -0.01 -0.02 -0.02 -0.00

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
CING
35GF Score
Cingulate Inc CING
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Cingulate (CING) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cingulate and its competitors.
Is Cingulate's Payments of Debt too high?
Cingulate's current Payments of Debt is $0.00 Mil. Overall, Cingulate has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Payments of Debt compare to IMA and MCRB?
Cingulate's Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cingulate and its competitors. Cingulate's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Cingulate's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Cingulate (CING), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
35GF Score

Get the complete analysis for CING

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.46
Price